Chembio to Present at the LD Micro VI: The Main Event Conference

Chembio to Present at the LD Micro VI: The Main Event Conference

MEDFORD, N.Y., Dec. 3, 2013 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.
(Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious
diseases, announces that Lawrence A. Siebert, Chief Executive Officer, will
present at the LD Micro VI: The Main Event Conference to be held December 3 –
5, 2013 in Los Angeles, CA. Mr. Siebert will be presenting at 10:00 am (PT) on
Thursday, December 5^th, Track Four. One-on-one meetings with investors will
be held during the conference to discuss the Company's strategy for continued
growth. To schedule a meeting with Chembio management, please call conference
organizers at 408-457-1042.  Attendance at the conference is by invitation

The Chembio presentation webcast will be available for public access via the
Investor Relations section of the Chembio corporate website,
or at where it will be archived for 90

For the sixth year, the LD Micro VI: The Main Event Conference will showcase
hundreds of small and micro cap companies to the investment community.

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets
proprietary rapid diagnostic tests in the growing $10 billion point-of-care
testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests
are marketed in the U.S. by Alere, Inc. Chembio markets its HIV STAT-PAK® line
of rapid HIV tests internationally to government and donor-funded programs
directly and through distributors. Chembio has developed a patented
point-of-care test platform technology, the Dual Path Platform (DPP®)
technology, which has significant advantages over lateral-flow technologies.
This technology is providing Chembio with a significant pipeline of business
opportunities for the development and manufacture of new products based on
DPP®. Headquartered in Medford, NY, with approximately 200 employees, Chembio
is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S.
Department of Agriculture (USDA), and is certified for the global market under
the International Standards Organization (ISO) directive 13.485. For more
information, please visit:

Forward-Looking Statements

Statements contained herein that are not historical facts may be
forward-looking statements within the meaning of the Securities Act of 1933,
as amended. Forward-looking statements include statements regarding the
intent, belief or current expectations of the Company and its management. Such
statements, which are estimates only, reflect management's current views, are
based on certain assumptions, and involve risks and uncertainties. Actual
results, events, or performance may differ materially from the above
forward-looking statements due to a number of important factors, and will be
dependent upon a variety of factors, including, but not limited to Chembio's
ability to obtain additional financing and to obtain regulatory approvals in a
timely manner, as well as the demand for Chembio's products. Chembio
undertakes no obligation to publicly update these forward-looking statements
to reflect events or circumstances that occur after the date hereof or to
reflect any change in Chembio's expectations with regard to these
forward-looking statements or the occurrence of unanticipated events. Factors
that may impact Chembio's success are more fully disclosed in Chembio's most
recent public filings with the U.S. Securities and Exchange Commission.

CONTACT: Chembio Diagnostics
         Susan Norcott
         (631) 924-1135, ext. 125
         Vida Strategic Partners (investors)
         Stephanie C. Diaz
         (415) 675-7401
Press spacebar to pause and continue. Press esc to stop.